Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Focal SBRT for Unifocal Prostate Cancer
NCT05616650Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2023
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Pathologic Complete Response Rate at 2 years. Started Oct 2023; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05616650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616650.